Skip to content
10-Q

Quarterly Report

ANEBULO PHARMACEUTICALS, INC. ANEB

0001493152-25-006893

← back to feed
Filed
Feb 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Feb 6, 2025 41.08M sh
Cash And Equivalents Q2 2025 · Dec 31, 2024 $15M
Cash And Equivalents Q2 2025 · Jun 30, 2024 $3.09M
Total Liabilities Q2 2025 · Dec 31, 2024 $878.8K
Total Liabilities Q2 2025 · Jun 30, 2024 $260.58K
Current Assets Q2 2025 · Dec 31, 2024 $15.4M
Current Assets Q2 2025 · Jun 30, 2024 $3.51M
Total Assets Q2 2025 · Dec 31, 2024 $15.84M
Total Assets Q2 2025 · Jun 30, 2024 $4.07M
Shares Diluted Q2 2025 · Dec 31, 2023 25.79M sh
Shares Diluted Q2 2025 · Dec 31, 2023 25.71M sh
Operating Cash Flow Q2 2025 · Dec 31, 2023 −$4.54M
Stockholders Equity Q2 2025 · Dec 31, 2023 $6.49M
Stockholders Equity Q2 2025 · Sep 30, 2023 $8.33M
Stockholders Equity Q2 2025 · Jun 30, 2023 $10.6M
Eps Diluted Q2 2025 · Dec 31, 2023 −$0.11
Eps Diluted Q2 2025 · Dec 31, 2023 −$0.20
Eps Basic Q2 2025 · Dec 31, 2023 −$0.11
Eps Basic Q2 2025 · Dec 31, 2023 −$0.20
Sga Expense Q2 2025 · Dec 31, 2023 $1.7M
Sga Expense Q2 2025 · Dec 31, 2023 $2.97M
Rd Expense Q2 2025 · Dec 31, 2023 $1.06M
Rd Expense Q2 2025 · Dec 31, 2023 $2.33M
Net Income Q2 2025 · Dec 31, 2023 −$2.72M
Net Income Q2 2025 · Dec 31, 2023 −$5.2M
Net Income Q2 2025 · Sep 30, 2023 −$2.48M
Operating Income Q2 2025 · Dec 31, 2023 −$2.76M
Operating Income Q2 2025 · Dec 31, 2023 −$5.3M